{"id":"W2900635510","doi":"10.1136/annrheumdis-2018-eular.1275","title":"THU0323 Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis","year":2018,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Autoimmune and Inflammatory Disorders Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Allergan; Incyte; Momenta Pharmaceuticals; Dermira; Genentech; Valeant Pharmaceuticals International; Sanofi; Sun Pharma; Zynerba Pharmaceuticals; Regeneron Pharmaceuticals; Novartis Pharma; Novartis; Amgen; Pfizer; Horizon Pharma; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Tofacitinib; Medicine; Psoriatic arthritis; Internal medicine; Adalimumab; Clinical endpoint; Janus kinase inhibitor; Psoriasis; Psoriasis Area and Severity Index; Placebo; Arthritis; Rheumatoid arthritis; Clinical trial; Gastroenterology; Surgery; Dermatology; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001982115,0.0001666609,0.0005177634,0.0001335282,0.00006896108,0.00001334824,0.0002436689,0.00003084871,0.0001637176],"category_scores_gemma":[0.0005987092,0.000102847,0.000177436,0.0002732289,0.00052458,0.0001442317,0.0001037651,0.00008895942,0.00001142725],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001103373,"about_ca_system_score_gemma":0.0002464596,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008354425,"about_ca_topic_score_gemma":0.00001203854,"domain_scores_codex":[0.9980955,0.0001249505,0.0005922636,0.0001826744,0.0007248858,0.0002797345],"domain_scores_gemma":[0.9984401,0.00008844976,0.0002888507,0.0006095345,0.0004088846,0.0001641377],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00486404,0.002398079,0.8514752,0.00160814,0.0004261355,0.000004335311,0.001014923,0.00001964105,0.0001267308,0.0003878088,0.001282268,0.1363927],"study_design_scores_gemma":[0.002467238,0.0005677087,0.9918948,0.002204788,0.00007240763,2.289063e-7,0.0001495099,0.0001236766,0.001363924,0.0009203057,0.0001201245,0.0001152256],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965117,0.001666586,0.00001182591,0.000573965,0.00004958743,0.0007403277,0.0001278661,0.00001707346,0.0003010784],"genre_scores_gemma":[0.9993322,0.0003242401,0.00003277466,0.0001570839,0.00001339393,0.00003129091,0.00002989416,0.00002028662,0.00005882056],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1404197,"threshold_uncertainty_score":0.419398,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0273525534853502,"score_gpt":0.2841176598579625,"score_spread":0.2567651063726123,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}